T helper 17 cell differentiation and activity

T helper 17 (Th17) cell differentiation and activity represent a critical immunological pathway characterized by the development of a distinct lineage of CD4+ T cells (NIH, 2021). These cells are defined by their production of proinflammatory cytokines, most notably IL-17A, IL-17F, and IL-22 (ThermoFisher, 2021). The differentiation process is initiated by a specific cytokine environment, including IL-6 and TGF-β, which activates the master transcription factor Retinoic acid receptor-related orphan receptor gamma t (RORγt) via STAT3 signaling (NIH, 2015). IL-23 subsequently plays a vital role in the expansion and maintenance of the Th17 phenotype (Cusabio, 2021). While Th17 cells are essential for host defense against extracellular bacteria and fungi, their dysregulation is a major driver of autoimmune and chronic inflammatory diseases such as psoriasis and multiple sclerosis (NIH, 2021). Therapeutic strategies targeting this pathway include monoclonal antibodies that neutralize IL-17 or IL-23, as well as small-molecule inhibitors of RORγt (ResearchGate, 2021). These treatments have demonstrated high efficacy in conditions like psoriasis and ankylosing spondylitis (NIH, 2021). However, modulating this pathway carries risks, such as increased susceptibility to mucocutaneous candidiasis and potential exacerbation of inflammatory bowel disease (NIH, 2021).

Other names

Th17 pathwayTh17 cell developmentTh17 lineage commitmentIL-23/IL-17 axis

Therapeutic modulation of this pathway involves the neutralization of effector cytokines (IL-17A, IL-17F), blockade of their receptors (IL-17RA), inhibition of upstream polarizing cytokines (IL-23, IL-12), or inverse agonism of the master transcription factor RORγt to suppress Th17 lineage commitment and activity.